Literature DB >> 28713678

Drug development against the hippo pathway in mesothelioma.

Gavitt A Woodard1, Yi-Lin Yang1, Liang You1, David M Jablons1.   

Abstract

Advances in the treatments for malignant pleural mesothelioma (MPM) have been disappointing until recently. Conventional cytotoxic drugs fail in MPM in part because they do not address the cancer stem cell population or stem cell pathways that drive tumor resistance and resurgence following treatment. The Hippo stem cell pathway regulates cell contact inhibition with tumor suppressor genes such as NF2 (Neurofibromatosis 2) upstream controlling YAP (Yes-associated protein 1) oncogenes. NF2 is mutated in 40-50% of all MPM and downstream YAP is constitutively active in greater than 70% of MPM, making the downstream YAP/TEAD (transcriptional enhancer associate domain) complex the ultimate target. Novel small molecule YAP inhibitors are showing promising results in preclinical studies and may prove to be effective chemotherapy drugs in MPM.

Entities:  

Keywords:  Cancer stem cell; Neurofibromatosis type 2 (NF2); Yes-associated protein (YAP); small molecule inhibitors

Year:  2017        PMID： 28713678      PMCID： PMC5504108          DOI： 10.21037/tlcr.2017.06.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  56 in total

1.  The Hippo-YAP signaling pathway and contact inhibition of growth.

Authors:  Barry M Gumbiner; Nam-Gyun Kim
Journal:  J Cell Sci       Date:  2014-02-15       Impact factor: 5.285

2.  Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma.

Authors:  Robin Tranchant; Lisa Quetel; Anne Tallet; Clement Meiller; Annie Renier; Leanne de Koning; Aurelien de Reynies; Francoise Le Pimpec-Barthes; Jessica Zucman-Rossi; Marie-Claude Jaurand; Didier Jean
Journal:  Clin Cancer Res       Date:  2016-12-21       Impact factor: 12.531

3.  YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers.

Authors:  Giorgio G Galli; Matteo Carrara; Wei-Chien Yuan; Christian Valdes-Quezada; Basanta Gurung; Brian Pepe-Mooney; Tinghu Zhang; Geert Geeven; Nathanael S Gray; Wouter de Laat; Raffaele A Calogero; Fernando D Camargo
Journal:  Mol Cell       Date:  2015-10-01       Impact factor: 17.970

4.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Authors:  Gérard Zalcman; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Frédéric Rivière; Henri Janicot; Radj Gervais; Chrystèle Locher; Bernard Milleron; Quan Tran; Marie-Paule Lebitasy; Franck Morin; Christian Creveuil; Jean-Jacques Parienti; Arnaud Scherpereel
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

Review 5.  The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.

Authors:  Matteo Santucci; Tatiana Vignudelli; Stefania Ferrari; Marco Mor; Laura Scalvini; Maria Laura Bolognesi; Elisa Uliassi; Maria Paola Costi
Journal:  J Med Chem       Date:  2015-03-11       Impact factor: 7.446

Review 6.  The Hippo signaling pathway and stem cell biology.

Authors:  Azucena Ramos; Fernando D Camargo
Journal:  Trends Cell Biol       Date:  2012-05-31       Impact factor: 20.808

7.  Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor.

Authors:  Shiva Keshava; Sanghamitra Sahoo; Torry A Tucker; Steven Idell; L Vijaya Mohan Rao; Usha R Pendurthi
Journal:  Cancer Res       Date:  2013-03-28       Impact factor: 12.701

8.  Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1.

Authors:  Run Fan; Nam-Gyun Kim; Barry M Gumbiner
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

Review 9.  Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities.

Authors:  Venessa T Chin; Adnan M Nagrial; Angela Chou; Andrew V Biankin; Anthony J Gill; Paul Timpson; Marina Pajic
Journal:  Expert Rev Mol Med       Date:  2015-10-28       Impact factor: 5.600

10.  Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins.

Authors:  B V V G Reddy; Kenneth D Irvine
Journal:  Dev Cell       Date:  2013-03-11       Impact factor: 12.270
View more
  12 in total

1.  The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.

Authors:  Ayumi Kaneda; Toshihiro Seike; Tomohiro Danjo; Takahiro Nakajima; Nobumasa Otsubo; Daisuke Yamaguchi; Yoshiro Tsuji; Kaori Hamaguchi; Mai Yasunaga; Yoichi Nishiya; Michihiko Suzuki; Jun-Ichi Saito; Rie Yatsunami; Satoshi Nakamura; Yoshitaka Sekido; Kiyotoshi Mori
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 2.  Progress in the Management of Malignant Pleural Mesothelioma in 2017.

Authors:  Amanda J McCambridge; Andrea Napolitano; Aaron S Mansfield; Dean A Fennell; Yoshitaka Sekido; Anna K Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I Pass; Michele Carbone; Haining Yang; Tobias Peikert
Journal:  J Thorac Oncol       Date:  2018-03-08       Impact factor: 15.609

3.  Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway.

Authors:  Juan Mo; Jean-Philippe Brosseau; Zhiguo Chen; Tracey Shipman; Yong Wang; Chung-Ping Liao; Jonathan M Cooper; Robert J Allaway; Sara J C Gosline; Justin Guinney; Thomas J Carroll; Lu Q Le
Journal:  Cancer Discov       Date:  2018-10-22       Impact factor: 39.397

Review 4.  New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.

Authors:  Marika Rossini; Paola Rizzo; Ilaria Bononi; Anthony Clementz; Roberto Ferrari; Fernanda Martini; Mauro G Tognon
Journal:  Front Oncol       Date:  2018-04-03       Impact factor: 6.244

Review 5.  Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.

Authors:  Yoshitaka Sekido
Journal:  Cancers (Basel)       Date:  2018-03-22       Impact factor: 6.639

6.  Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.

Authors:  Ping-Chih Hsu; Jinbai Miao; Yu-Cheng Wang; Wen-Qian Zhang; Yi-Lin Yang; Chih-Wei Wang; Cheng-Ta Yang; Zhen Huang; Joanna You; Zhidong Xu; David M Jablons; Liang You
Journal:  J Cell Mol Med       Date:  2018-03-24       Impact factor: 5.310

7.  MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.

Authors:  Elodie Maille; Solenn Brosseau; Vincent Hanoux; Christian Creveuil; Claire Danel; Emmanuel Bergot; Arnaud Scherpereel; Julien Mazières; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Alexandra Langlais; Franck Morin; Guénaëlle Levallet; Gérard Zalcman
Journal:  Br J Cancer       Date:  2019-02-11       Impact factor: 7.640

8.  Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.

Authors:  Christin Lund-Andersen; Sigve Nakken; Ståle Nygård; Bastian Fromm; Lars B Aasheim; Ben Davidson; Lars Julsrud; Torveig W Abrahamsen; Annette T Kristensen; Brit Dybdahl; Stein G Larsen; Eivind Hovig; Kjersti Flatmark
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-04-01

9.  Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma.

Authors:  Claudio Pulito; Etleva Korita; Andrea Sacconi; Mariacristina Valerio; Luca Casadei; Federica Lo Sardo; Federica Mori; Maria Ferraiuolo; Giuseppe Grasso; Anna Maidecchi; Jacopo Lucci; Marius Sudol; Paola Muti; Giovanni Blandino; Sabrina Strano
Journal:  J Exp Clin Cancer Res       Date:  2019-08-09

Review 10.  Translating current basic research into future therapies for neurofibromatosis type 1.

Authors:  Jean-Philippe Brosseau; Chung-Ping Liao; Lu Q Le
Journal:  Br J Cancer       Date:  2020-05-22       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.